73.68
1.28%
0.93
Pre-market:
74.51
0.83
+1.13%
Praxis Precision Medicines Inc stock is traded at $73.68, with a volume of 332.55K.
It is up +1.28% in the last 24 hours and up +0.66% over the past month.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.
See More
Previous Close:
$72.75
Open:
$72.59
24h Volume:
332.55K
Relative Volume:
1.15
Market Cap:
$1.37B
Revenue:
$1.77M
Net Income/Loss:
$-123.74M
P/E Ratio:
-24.32
EPS:
-3.03
Net Cash Flow:
$-95.21M
1W Performance:
-9.84%
1M Performance:
+0.66%
6M Performance:
+63.70%
1Y Performance:
+5,890%
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Name
Praxis Precision Medicines Inc
Sector
Industry
Phone
617-300-8460
Address
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
PRAX | 73.68 | 1.37B | 1.77M | -123.74M | -95.21M | -3.03 |
VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-19-23 | Initiated | Truist | Buy |
Jun-06-22 | Downgrade | Wedbush | Outperform → Neutral |
Dec-16-21 | Initiated | H.C. Wainwright | Buy |
Aug-26-21 | Initiated | BofA Securities | Buy |
Apr-26-21 | Initiated | William Blair | Outperform |
Nov-11-20 | Initiated | Wedbush | Outperform |
Nov-10-20 | Initiated | Cowen | Outperform |
Nov-10-20 | Initiated | Evercore ISI | Outperform |
Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Praxis Precision Medicines Inc Stock (PRAX) Latest News
Why Praxis Precision Medicines Stock Is Trading Higher Tuesday - MSN
Praxis Precision Medicines (NASDAQ:PRAX) Shares Gap Down Following Insider Selling - MarketBeat
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Bought by CIBC Asset Management Inc - MarketBeat
Alex Nemiroff Sells 8,239 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Stock - MarketBeat
Insider Selling: Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Insider Sells 5,188 Shares of Stock - MarketBeat
(PRAX) Proactive Strategies - Stock Traders Daily
Praxis Precision Medicines principal accounting officer sells $424,318 in stock - Investing.com India
Praxis Precision Medicines principal accounting officer sells $424,318 in stock By Investing.com - Investing.com Australia
Praxis Precision Medicines' general counsel sells shares worth $660,827 - Investing.com
Praxis Precision Medicines (NASDAQ:PRAX) Trading Down 7.9%Should You Sell? - MarketBeat
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Cormorant Asset Management's Strategic Acquisition in Praxis Pre - GuruFocus.com
Verition Fund Management LLC Adjusts Stake in Praxis Precision M - GuruFocus.com
Capital Research Global Investors Acquires New Stake in Praxis P - GuruFocus.com
Equities Analysts Offer Predictions for PRAX FY2024 Earnings - MarketBeat
FY2024 Earnings Estimate for PRAX Issued By HC Wainwright - MarketBeat
Praxis Precision Medicines Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
HC Wainwright Reiterates "Buy" Rating for Praxis Precision Medicines (NASDAQ:PRAX) - MarketBeat
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Q3 2024 Earnings Call Transcript - Insider Monkey
Praxis Precision Medicines Inc (PRAX) Is Worth A Look Now, Despite -5.10% Loss From High - Stocks Register
Praxis Precision Medicines Inc (PRAX) Q3 2024 Earnings Call Highlights: Strong Cash Position ... - Yahoo Finance
Praxis Precision Medicines Inc (PRAX) Q3 2024 Earnings Call Highlights: Strong Cash Position ... By GuruFocus - Investing.com Canada
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results - citybiz
Praxis Precision Medicines Reports Q3 2024 Results and Progress - TipRanks
Praxis Precision Medicines, Inc. (PRAX) Reports Q3 Loss, Misses Revenue Estimates - MSN
Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences - GlobeNewswire
Praxis Precision Medicines to Present at Three Major Healthcare Conferences in November | PRAX Stock News - StockTitan
Praxis Precision Advances CNS Disorder Therapies - TipRanks
Q3 2024 Praxis Precision Medicines Inc Earnings Call Transcript - GuruFocus.com
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial - The Bakersfield Californian
How the (PRAX) price action is used to our Advantage - Stock Traders Daily
Vanguard Group Inc's Strategic Acquisition in Praxis Precision M - GuruFocus.com
Assenagon Asset Management S.A. Decreases Stock Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Praxis Precision Medicines (PRAX) to Release Quarterly Earnings on Wednesday - MarketBeat
Praxis Precision Medicines to Announce Third Quarter 2024 - GlobeNewswire
Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024 - The Manila Times
(PRAX) Trading Advice - Stock Traders Daily
Moody Aldrich Partners LLC Purchases 7,224 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate - Yahoo Finance
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Praxis Precision To Report Aria Study Data In June - RTTNews
Will Praxis Precision Hit The Targets? - RTTNews
Praxis Precision Medicines revises executive severance terms - Investing.com
Where are the Opportunities in (PRAX) - Stock Traders Daily
Praxis Precision Medicines revises executive severance terms By Investing.com - Investing.com Australia
Praxis Precision To Reveal Key Trial Data On Essential Tremors - RTTNews
Dimensional Fund Advisors LP Sells 8,152 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Praxis Precision shares get boost on DEE space acquisition interest - Investing.com India
Praxis Precision Medicines (NASDAQ:PRAX) Reaches New 52-Week HighHere's Why - MarketBeat
Praxis Precision shares get boost on DEE space acquisition interest By Investing.com - Investing.com South Africa
Praxis Precision Medicines Inc Stock (PRAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):